|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Atorvastatin calcium]] |
| {{Atorvastatin}}
| |
| {{CMG}}; {{AE}} {{PB}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to [[hypercholesterolemia]]. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and [[cholesterol]] and other nonpharmacologic measures alone has been inadequate. In patients with [[CHD]] or multiple risk factors for CHD, LIPITOR can be started simultaneously with diet.
| |
| | |
| ====Prevention of Cardiovascular Disease====
| |
| | |
| In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, [[smoking]], [[hypertension]], low [[HDL]]-C, or a family history of early coronary heart disease, LIPITOR is indicated to:
| |
| | |
| * Reduce the risk of [[myocardial infarction]]
| |
| * Reduce the risk of [[stroke]]
| |
| * Reduce the risk for [[revascularization]] procedures and [[angina]]
| |
| | |
| In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as [[retinopathy]], [[albuminuria]], [[smoking]], or [[hypertension]], LIPITOR is indicated to:
| |
| | |
| * Reduce the risk of [[myocardial infarction]]
| |
| * Reduce the risk of [[stroke]]
| |
| | |
| In patients with clinically evident coronary heart disease, LIPITOR is indicated to:
| |
| | |
| * Reduce the risk of non-fatal [[myocardial infarction]]
| |
| * Reduce the risk of fatal and non-fatal [[stroke]]
| |
| * Reduce the risk for [[revascularization]] procedures
| |
| * Reduce the risk of hospitalization for [[CHF]]
| |
| * Reduce the risk of [[angina]]
| |
| | |
| ====Hyperlipidemia====
| |
| | |
| LIPITOR is indicated:
| |
| | |
| * As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary [[hypercholesterolemia]] (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb);
| |
| | |
| * As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV);
| |
| | |
| * For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet;
| |
| | |
| * To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable;
| |
| | |
| * As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present:
| |
| | |
| : [[LDL]]-C remains ≥ 190 mg/dL or
| |
| : [[LDL]]-C remains ≥ 160 mg/dL and:
| |
| :: a) there is a positive family history of premature cardiovascular disease
| |
| :: b) or two or more other CVD risk factors are present in the pediatric patient
| |
| | |
| ====Limitations of Use====
| |
| | |
| LIPITOR has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LIPITOR (ATORVASTATIN CALCIUM) TABLET, FILM COATED [PARKE-DAVIS DIV OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |